These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Senicapoc: a potent candidate for the treatment of a subset of hereditary xerocytosis caused by mutations in the Gardos channel. Rapetti-Mauss R; Soriani O; Vinti H; Badens C; Guizouarn H Haematologica; 2016 Nov; 101(11):e431-e435. PubMed ID: 27443288 [No Abstract] [Full Text] [Related]
4. A mutation in the Gardos channel is associated with hereditary xerocytosis. Rapetti-Mauss R; Lacoste C; Picard V; Guitton C; Lombard E; Loosveld M; Nivaggioni V; Dasilva N; Salgado D; Desvignes JP; Béroud C; Viout P; Bernard M; Soriani O; Vinti H; Lacroze V; Feneant-Thibault M; Thuret I; Guizouarn H; Badens C Blood; 2015 Sep; 126(11):1273-80. PubMed ID: 26148990 [TBL] [Abstract][Full Text] [Related]
5. Red blood cell Gardos channel (KCNN4): the essential determinant of erythrocyte dehydration in hereditary xerocytosis. Rapetti-Mauss R; Picard V; Guitton C; Ghazal K; Proulle V; Badens C; Soriani O; Garçon L; Guizouarn H Haematologica; 2017 Oct; 102(10):e415-e418. PubMed ID: 28619848 [No Abstract] [Full Text] [Related]
6. Mutations in the Gardos channel (KCNN4) are associated with hereditary xerocytosis. Glogowska E; Lezon-Geyda K; Maksimova Y; Schulz VP; Gallagher PG Blood; 2015 Sep; 126(11):1281-4. PubMed ID: 26198474 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the potassium channel K Staal RGW; Khayrullina T; Zhang H; Davis S; Fallon SM; Cajina M; Nattini ME; Hu A; Zhou H; Poda SB; Zorn S; Chandrasena G; Dale E; Cambpell B; Biilmann Rønn LC; Munro G; Mӧller T Eur J Pharmacol; 2017 Jan; 795():1-7. PubMed ID: 27876619 [TBL] [Abstract][Full Text] [Related]
8. Novel Gardos channel mutations linked to dehydrated hereditary stomatocytosis (xerocytosis). Andolfo I; Russo R; Manna F; Shmukler BE; Gambale A; Vitiello G; De Rosa G; Brugnara C; Alper SL; Snyder LM; Iolascon A Am J Hematol; 2015 Oct; 90(10):921-6. PubMed ID: 26178367 [TBL] [Abstract][Full Text] [Related]
9. Characterisation of Asp669Tyr Piezo1 cation channel activity in red blood cells: an unexpected phenotype. Pérès L; Monedero Alonso D; Nudel M; Figeac M; Bruge J; Sebda S; Picard V; El Nemer W; Preudhomme C; Rose C; Egée S; Bouyer G Br J Haematol; 2021 Jul; 194(1):e51-e55. PubMed ID: 33973227 [No Abstract] [Full Text] [Related]
16. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043). Ataga KI; Reid M; Ballas SK; Yasin Z; Bigelow C; James LS; Smith WR; Galacteros F; Kutlar A; Hull JH; Stocker JW; Br J Haematol; 2011 Apr; 153(1):92-104. PubMed ID: 21323872 [TBL] [Abstract][Full Text] [Related]
17. Repurposing the K Lee RD; Chen YJ; Nguyen HM; Singh L; Dietrich CJ; Pyles BR; Cui Y; Weinstein JR; Wulff H Transl Stroke Res; 2024 Jun; 15(3):518-532. PubMed ID: 37088858 [TBL] [Abstract][Full Text] [Related]
18. Haemoglobin response to senicapoc in patients with sickle cell disease: a re-analysis of the Phase III trial. Ataga KI; Staffa SJ; Brugnara C; Stocker JW Br J Haematol; 2021 Mar; 192(5):e129-e132. PubMed ID: 33527340 [No Abstract] [Full Text] [Related]